Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
$103.09
-$4.73(-3.73%)
At close: 4:00 PM EST
$103.09
-$4.73(-3.73%)
Day’s Range― - ―
52-Week Range$81.20 - $129.27
Previous CloseN/A
Volume316.50K
Average Volume (3M)707.61K
Market Cap
$26.86B
Enterprise Value$7.11B
Total Cash (Recent Filing)$14.53B
Total Debt (Recent Filing)$245.40M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 10, 2026EPS Estimate
-0.25Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding240,398,730
10 Day Avg. Volume903,072
30 Day Avg. Volume707,611
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.36
Price to Sales (P/S)9.62
P/FCF Ratio-108.15
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.73
Enterprise Value/Ebitda-68.81
Forecast
1Y Price Target
$139.60Price Target Upside35.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI And Technological AdvancementsBioNTech's investment in AI platforms like Nucleotide Transformer and InstaNovo is expected to enhance genome exploration and protein development, offering a competitive advantage.
Financial Performance And GuidanceBioNTech raised 2025 revenue guidance and lowered expense guidance, reflecting positive financial adjustments and strong future financial expectations.
Oncology Pipeline DevelopmentBioNTech is focusing on developing their oncology pipeline with combination strategies, highlighting their proactive approach and commitment to advancing treatment options.
Bears Say
COVID-19 Vaccine Market ChallengesShifting policy and market dynamics in the COVID-19 vaccine sector remain a challenge, possibly affecting sales and market position.
Market Adoption RisksDespite a revenue beat, there is continued risk for long-term adoption of COVID-19 vaccines, potentially affecting future revenues.
Pipeline Advancement DelaysThe clinical pipeline is advancing slower than management's guidance, with ongoing delays in key catalysts, which could impact investor confidence.
BioNTech SE News
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $81.20 and its highest was $129.27 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $26.86B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2026 which is in 114 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 03, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$1.107 by $0.967.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -0.25.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 240,398,730 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$0.14 in its last earnings report, beating expectations of -$1.107. Following the earnings report the stock price went up 0.048%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$139.60 (35.42% Upside)
$139.60 (35.42% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 275.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $417.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.45%
12-Months-Change
Fundamentals
Return on Equity
-2.94%
Trailing 12-Months
Asset Growth
0.30%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a biotechnology company based in Germany that focuses on the development of personalized immunotherapies for cancer and other serious diseases. The company utilizes its proprietary mRNA technology platform to create innovative therapeutics and vaccines, including its widely known COVID-19 vaccine developed in partnership with Pfizer. BioNTech operates primarily in the biopharmaceutical sector, with a strong emphasis on personalized medicine and immune-oncology.
BNTX Company Deck
BNTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioNTech showed strong progress in its oncology programs and financial position, highlighted by increased revenue and strategic advancements. However, challenges include significant financial losses and delays in product submissions due to regulatory discussions.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$139.60
▲(35.42% Upside)
Technical Analysis
Ownership Overview
0.36% Insiders
5.23% Mutual Funds
10.50% Other Institutional Investors
83.12% Public Companies and
Individual Investors